Journal
WORLD JOURNAL OF CLINICAL CASES
Volume 8, Issue 8, Pages 1361-1384Publisher
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.12998/wjcc.v8.i8.1361
Keywords
VSL#3; Intestinal barrier function; Chronic diseases; Intestinal microbial balance; Cytokines; Therapeutic use
Categories
Funding
- Innovative Talent Support Program of the Institution of Higher Learning in Liaoning Province [2018-478]
- Innovative Talents of Science and Technology Support Program of Young and Middle People of Shenyang [RC170446]
Ask authors/readers for more resources
Probiotics are known as live microorganisms and have been proven to have a health effect on hosts at the proper dose. Recently, a kind of probiotic mixture including eight live bacterial strains, VSL#3, has attracted considerable attention for its combined effect. VSL#3 is the only probiotic considered as a kind of medical food; it mainly participates in the regulation of the intestinal barrier function, including improving tight junction protein function, balancing intestinal microbial composition, regulating immune-related cytokine expression and so on. The objective of this review is to discuss the treatment action and mechanism for the administration of VSL#3 in chronic diseases of animals and humans (including children). We found that VSL#3 has a therapeutic or preventive effect in various systemic diseases per a large number of studies, including digestive systemic diseases (gastrointestinal diseases and hepatic diseases), obesity and diabetes, allergic diseases, nervous systemic diseases, atherosclerosis, bone diseases, and female reproductive systemic diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available